Skip to main content

What We Do

CKc funds innovative research and educates for change.

Ckc Options Created

We have created over 787 treatment Options

To date, CKc has created 787 treatment options for children whose only other alternative was hospice.
Millions Invested in Research

$3.9 million invested in pediatric cancer research

CKc funds innovative clinical trial research, supports new talent through young investigator grants, and increases access to cutting-edge therapies through program grants.
Grant Awarded

36 Grants Awarded

Since 2014, CKc has awarded grants that provide access to innovative treatment options across the United States, in D.C., Canada, Scotland, and Switzerland.
First-of-its-Kind Research

94% of CKc-funded clinical trials are first-of-their-kind

Pediatric cancers and adult cancers are different. Standard cancer treatments impact children’s bodies differently than adults’ bodies. We prioritize funding treatments designed specifically to treat pediatric cancers while minimizing the brutal side-effects of standard treatments.

Learn about the full impact CKc has on pediatric cancer research in our annual report.

2024 Impact Report in someone's hands

CKc Educates for Change

Most people are unaware of the realities of pediatric cancers. We believe that once people learn the truth of pediatric cancer they will demand change. It’s our mission to educate and empower everyone.

The importance of educating people on the impacts of pediatric cancer cannot be overstated. Childhood cancer is a devastating disease that can have a profound impact on the lives of children and their families. It is important for people to understand the challenges that children with cancer face, as well as the resources that are available to them.

Education can help to raise awareness of pediatric cancer and its effects, and it can also help to reduce the stigma associated with the disease. By educating people about pediatric cancer, we can help to ensure that all children have access to the best possible care.